Figure S12 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

This is a Quantitative Study study.

Key Points

Differential analysis of GSEA reveals significant pathways modified by ulixertinib and MRTX1719.
Combination treatment shows enhanced pathway regulation compared to single-agent therapies.
Findings emphasize the potential of targeting specific pathways in MTAP-deleted cancer for improved outcomes.
Further exploration of drug interactions could lead to more effective treatment strategies for this cancer type.

Differential GSEA analyzes pathways altered by ERK1/2 inhibitor ulixertinib and MRTX1719 in MTAP-deleted cancer.

Figure S12. Differential GSEA by RNAseq reveals pathways modified by ERK1/2 inhibitor ulixertinib, MTAC-PRMT5i MRTX1719, or the combination.

No takes yet. Share an insight, caveat, or question.

Knoll et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share